Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management CAMBRIDGE, England, March 9, 2021 /PRNewswire/ -- NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces the close of a £15.2m (US $21m) Series B round. The...